Acorda Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q1 2016 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Acorda Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2016 to Q1 2024.
  • Acorda Therapeutics, Inc. Costs and Expenses for the quarter ending March 31, 2024 was $39.9M, a 18.3% increase year-over-year.
  • Acorda Therapeutics, Inc. Costs and Expenses for the twelve months ending March 31, 2024 was $389M, a 162% increase year-over-year.
  • Acorda Therapeutics, Inc. annual Costs and Expenses for 2023 was $383M, a 149% increase from 2022.
  • Acorda Therapeutics, Inc. annual Costs and Expenses for 2022 was $154M, a 26% decline from 2021.
  • Acorda Therapeutics, Inc. annual Costs and Expenses for 2021 was $208M, a 9.93% decline from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $389M $39.9M +$6.18M +18.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $383M $285M +$254M +814% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 $128M $30.2M -$8.27M -21.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $137M $33.3M -$11.7M -25.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $148M $33.7M -$5.5M -14% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $154M $31.2M -$17.3M -35.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 $171M $38.5M -$16M -29.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $187M $45M -$2.51M -5.28% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $190M $39.2M -$18.4M -31.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $208M $48.5M -$68M -58.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 $276M $54.5M +$17.4M +47% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $259M $47.5M +$4.31M +9.98% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $254M $57.6M +$23.4M +68.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 $231M $117M +$80.5M +224% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-18
Q3 2020 $150M $37.1M -$270M -87.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $421M $43.2M -$30.3M -41.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $451M $34.3M -$53.2M -60.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $504M $36M -$82.4M -69.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 $586M $307M +$193M +168% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $394M $73.4M -$20.8M -22.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $415M $87.5M -$18.2M -17.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $433M $118M -$288M -70.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 $721M $115M -$28.7M -20% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $750M $94.3M -$42.5M -31.1% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $792M $106M -$28.9M -21.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $821M $406M +$267M +191% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-28
Q3 2017 $555M $143M +$2.14M +1.52% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $552M $137M -$4.75M -3.36% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $557M $135M +$1.56M +1.18% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $556M $140M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $141M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $141M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $133M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.